Drugs / Divarasib
Trials 14
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT06835465 | Feb → May 2025 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06734208 | Jan → Nov 2025 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06690138 | Nov 2024 → Feb 2025 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06677957 | Nov → Dec 2024 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04929223 | Oct 2021 → Aug 2030 expected | colorectal cancer | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 1 | NCT04449874 | Jul 2020 → Dec 2027 expected | colorectal cancer, non-small cell lung carcinoma | Genentech, Inc. | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05789082 | Jun 2023 → Jan 2032 expected | non-small cell lung carcinoma | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04589845 | Jan 2021 → Sep 2032 expected | cancer | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04302025 | Nov 2020 → Nov 2026 expected | non-small cell lung carcinoma | Genentech, Inc. | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03178552 | Sep 2017 → Jun 2027 expected | non-small cell lung carcinoma | Hoffmann-La Roche | Active not recruiting | Mixed |
| Phase 34 trials · 1 met primary | ||||||
| Phase 3 | NCT07541170 | Sep 2026 → Jan 2032 expected | non-small cell lung carcinoma | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 3 | NCT06793215 | Oct 2025 → Nov 2028 expected | non-small cell lung carcinoma | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 3 | NCT06497556 | Sep 2024 → May 2026 overdue | non-small cell lung carcinoma | Hoffmann-La Roche | Active not recruiting | Met primary |
| Phase 3 | NCT05862285 | Jun 2023 → Mar 2033 expected | cancer | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT07783009 Background | — | non-small cell lung carcinoma | Genentech, Inc. | Available | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-07-02 | Hoffmann-La Roche | Results [Ad hoc announcement pursuant to Art. 53 LR] Roche’s divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancer roche.com ↗
The study met its primary and key secondary endpoint, with divarasib achieving clinically meaningful and statistically significant improvements in both progression-free survival (PFS) and overall survival (OS). |
| 2026-07-02 | Chugai Pharmaceutical | Results Roche’s Announcement Regarding divarasib (Announcement of Phase III Krascendo1 Study Results) chugai-pharm.co.jp ↗
Roche’s divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancer |
| 2026-07-01 | Genentech, Inc. | Results Genentech’s Divarasib Shows Superiority in Head-To-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer gene.com ↗
Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today positive results from the Phase III Krascendo 1 study evaluating divarasib, an investigational next-generation KRAS G12C inhibitor, against the approved, first generation KRAS G12C inhibitors sotorasib or adagrasib in patients with previously treated KRAS G12C non-small cell lung cancer (NSCLC). |
| 2026-07-01 | Genentech, Inc. | Results Genentech’s Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer gene.com ↗
The study met its primary and key secondary endpoint, with divarasib achieving clinically meaningful and statistically significant improvements in both progression-free survival (PFS) and overall survival (OS). |
All press releases naming this drug 4 releases
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | divarasib | “Divarasib (GDC-6036) is a covalent KRAS G12C inhibitor that was designed to have high potency and selectivity.” PMID 37611121 ↗ Aug 2023 |
| Known as | GDC-6036 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04449874 ↗ |
| Known as | RG-6330 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095236 ↗ |
| Known as | RO-7435846 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095236 ↗ |
| Action | Inhibit | “Divarasib (GDC-6036) is a covalent KRAS G12C inhibitor that was designed to have high potency and selectivity.” PMID 37611121 ↗ Aug 2023 |
| Modality | Small molecule | — CHEMBL5095236 ↗ |
| Route | Oral | “divarasib PO QD” NCT03178552 ↗ |
| Target | KRAS | “Divarasib (GDC-6036) is a covalent KRAS G12C inhibitor that was designed to have high potency and selectivity.” PMID 37611121 ↗ Aug 2023 |